If You're 50+ and Tired of Watching Tech Boom Without You, Read This

Impact · against what's priced in

The article serves as a marketing piece for SCHD's dividend-growth strategy amidst falling risk-free rates, but offers no material new catalysts for the underlying holdings. While the macro shift toward lower T-bill yields supports a rotation into value, the specific mentions of the constituent stocks are generic and do not change their fundamental valuations.

SCHD+0.30: No priced-in read yet

If You're 50+ and Tired of Watching Tech Boom Without You, Read This

What matters in this story

NewMarket Just Raised Its Dividend 8.3%. Here Are 2 More Under-the-Radar Dividend Stocks

If You're 50+ and Tired of Watching Tech Boom Without You, Read This

What matters in this story

NewMarket Just Raised Its Dividend 8.3%. Here Are 2 More Under-the-Radar Dividend Stocks

How each ticker is affected

Connected tickers

Track these names every morning.

Realty Income and 4 More High-Yield Dividend Stocks for November

AbbVie: 3 Key Takeaways for Long-Term Investors

ConocoPhillips: Drilling Toward Greater Returns

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%

If You're 50+ and Tired of Watching Tech Boom Without You, Read This

What matters in this story

Next reads from the same story arc

NewMarket Just Raised Its Dividend 8.3%. Here Are 2 More Under-the-Radar Dividend Stocks

If You're 50+ and Tired of Watching Tech Boom Without You, Read This

What matters in this story

Next reads from the same story arc

NewMarket Just Raised Its Dividend 8.3%. Here Are 2 More Under-the-Radar Dividend Stocks

How each ticker is affected

Connected tickers

Track these names every morning.

Realty Income and 4 More High-Yield Dividend Stocks for November

AbbVie: 3 Key Takeaways for Long-Term Investors

ConocoPhillips: Drilling Toward Greater Returns

$10,000 in Vanguard's Health Care ETF in 2004 Grew to $93,915, and It Still Charges 0.09%